Clinical Trial: Nexium Capsules Clinical Experience Investigation
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Nexium Capsules Clinical Experience Investigation
Brief Summary: The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
Detailed Summary: Nexium capsules Clinical Experience Investigation
Sponsor: AstraZeneca
Current Primary Outcome:
- Number of Adverse Drug Reactions [ Time Frame: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks ]
- Number of Adverse Drug Reactions [ Time Frame: Patients with duodenal ulcer: 6 weeks ]
- Number of Adverse Drug Reactions [ Time Frame: Patients with reflux oesophagitis: 8 weeks ]
- Number of Adverse Drug Reactions [ Time Frame: Patients with non-erosive reflux disease: 4 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: AstraZeneca
Dates:
Date Received: September 14, 2011
Date Started: September 2011
Date Completion:
Last Updated: April 14, 2014
Last Verified: April 2014